Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Trial Profile

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary) ; GPC3-CAR-T (Primary) ; Satricabtagene autoleucel (Primary) ; Sorafenib (Primary) ; Zevorcabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; B-cell leukaemia; B-cell lymphoma; B-cell prolymphocytic leukaemia; Carcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Liver cancer; Mantle-cell lymphoma; Multiple myeloma; Oesophageal cancer; Pancreatic cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jan 2024 According to a CARsgen media release, CT011 received IND clearance from the NMPA in 2019 for the treatment of patients with GPC3-positive solid tumor.
    • 18 Aug 2022 According to a CARsgen media release, a case report titled "Long Term Complete Response of Advanced Hepatocellular Carcinoma to Glypican-3 Specific Chimeric Antigen Receptor T-Cells plus Sorafenib, A case report", has been published in Frontiers in Immunology.
    • 18 Aug 2022 Results published in the CARsgen Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top